Want to see JP:197A full AI Analyst Report?
Tauns Laboratories, Inc. (197A) AI Stock Analysis
Top Page
Tauns Laboratories, Inc.
(TSE/TYO:197A)
The score is primarily supported by attractive valuation (low P/E and high dividend yield) and generally positive technical momentum. These positives are balanced by financial-performance risks, especially volatile cash generation (negative in 2026) alongside materially higher leverage, which increases sensitivity to any earnings or working-capital swings.
Tauns Laboratories, Inc. (197A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 52.45B
- Dividend Yield
- 5.70%
- Average Volume (3M)
- 225.56K
- Price to Earnings (P/E)
- 9.4
- Beta (1Y)
- 0.39
- Revenue Growth
- -22.86%
- EPS Growth
- -16.43%
- Country
- Japan
- Employees
- 271
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Tauns Laboratories, Inc. Business Overview & Revenue Model
Company Description
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an exten...
Tauns Laboratories, Inc. Financial Statement Overview
Summary
Strong reported profitability and improving net margin support the score, but it is materially offset by deteriorating/volatile cash flow (negative operating and free cash flow in 2026) and a sharp rise in leverage (debt-to-equity above 1.0 in 2026), which increases funding and earnings-quality risk.
Income Statement
78PositiveBalance Sheet
60NeutralCash Flow
35Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.37B | 14.37B | 18.63B | 18.43B | 15.67B | 17.46B |
| Gross Profit | 8.82B | 8.22B | 12.33B | 12.50B | 8.79B | 14.29B |
| EBITDA | 5.33B | 5.33B | 9.02B | 8.65B | 5.32B | 8.55B |
| Net Income | 5.50B | 5.50B | 6.32B | 5.77B | 3.03B | 4.48B |
Balance Sheet | ||||||
| Total Assets | 44.62B | 44.62B | 36.52B | 29.26B | 18.81B | 20.88B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 3.56B | 9.27B | 9.42B | 1.24B | 6.35B |
| Total Debt | 21.26B | 21.26B | 14.42B | 9.54B | 6.47B | 4.90B |
| Total Liabilities | 25.20B | 25.20B | 19.10B | 15.59B | 10.32B | 13.52B |
| Stockholders Equity | 19.42B | 19.42B | 17.42B | 13.67B | 8.49B | 7.36B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -6.61B | 2.14B | 5.97B | -4.32B | 8.39B |
| Operating Cash Flow | 0 | -2.83B | 6.82B | 9.94B | -3.16B | 10.69B |
| Investing Cash Flow | 0 | -6.18B | -9.26B | -4.11B | -1.62B | -2.68B |
| Financing Cash Flow | 0 | 3.30B | 2.28B | 2.36B | -330.20M | -3.66B |
Tauns Laboratories, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:197A, the sentiment is Negative. The current price of 491.00 is below the 20-day moving average (MA) of 507.25, below the 50-day MA of 508.60, and below the 200-day MA of 496.36, indicating a bearish trend. The MACD of -4.69 indicates Positive momentum. The RSI at 34.09 is Neutral, neither overbought nor oversold. The STOCH value of 17.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:197A.
Tauns Laboratories, Inc. Peers Comparison
Overall Rating
- JP:197A70Outperform
JP:239563Neutral
JP:454957Neutral
JP:455252Neutral
JP:456952Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:197A | 70Outperform | JPY 52.45B | 9.37 | ― | 5.70% | -22.86% | -16.43% |
| JP:2395 | 63Neutral | JPY 62.70B | 11.67 | ― | 3.32% | 1.72% | 6.07% |
| JP:4549 | 57Neutral | JPY 76.06B | 41.05 | ― | 2.51% | 3.92% | -52.01% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4552 | 52Neutral | JPY 67.32B | -19.55 | ― | 3.68% | 3.05% | -67.53% |
| JP:4569 | 52Neutral | JPY 58.17B | 29.23 | ― | 4.25% | -4.71% | -78.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:197A | Tauns Laboratories, Inc. | 491.00 | -33.33 | -6.36% | |
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1506.00 | 99.20 | 7.05% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2307.00 | 3.99 | 0.17% | |
| JP:4552 | JCR Pharmaceuticals Co., Ltd. | 544.00 | -32.54 | -5.64% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1105.00 | -256.96 | -18.87% | |
| JP:368A | Kitazato Corporation | 1284.00 | -35.03 | -2.66% |
Tauns Laboratories, Inc. Corporate Events
Tauns Laboratories’ Profit Slides on Lower Sales as Cash Flow Turns Negative
Tauns Laboratories reported FY2026 net sales of ¥14.37 billion, down 22.9% year on year, with operating income halving to ¥4.20 billion and ordinary income falling 51.9%, while net income declined a milder 13% to ¥5.50 billion as profi...
Tauns Laboratories Books ¥3.9 Billion Government Subsidy as Special Gain
Tauns Laboratories has booked a special gain of ¥3,949 million in the fourth quarter of the fiscal year ending June 30, 2026, after receiving final approval for a government subsidy under Japan’s “Subsidy Program for Promoting Domest...
Tauns Laboratories Corrects Presentation of Operating Income Forecast Without Changing Outlook
Tauns Laboratories has issued a correction to its recently updated mid-term management plan, clarifying the way it presents its full-year operating income forecast for the fiscal year ending June 30, 2026. The company confirmed that the forecast rema...
Tauns Laboratories Revamps Mid-Term Plan With Strong Growth Targets
Tauns Laboratories has updated its mid-term management plan, shifting the covered period to the fiscal years ending June 2027 through June 2031 in response to changes in the business environment and the progress of its existing strategy. The new plan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026